SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report

Report for Clinical Trial NCT01352585

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

An Exploratory, Observational, Multicentre Study to Investigate the Impact of the Presence of JAK2 (V617F) Mutation on Treatment Response in Patients With Essential Thrombocythaemia Treated With XAGRID® (Anagrelide Hydrochloride)

This study is hypothesis-generating to explore the impact of JAK2 (V617F) mutation status on the treatment response to anagrelide hydrochloride

NCT01352585 Essential Thrombocythemia (ET)
MeSH: Thrombocytosis Thrombocythemia, Essential
HPO: Thrombocytosis

1 Interventions

Name: Anagrelide hydrochloride

Description: 0.5 mg hard capsules, dosing decisions will be made by the treating physician

Type: Drug

Anagrelide hydrochloride

Primary Outcomes

Description: A platelet count of ≤600x10^9/L after 12 months is considered at least a partial response.

Measure: Number of Patients With Platelet Count ≤600x10^9/L After 12 Months

Time: 1 year

Secondary Outcomes

Description: A platelet count of ≤400x10^9/L after 12 months is considered a complete response.

Measure: Number of Patients With Platelet Count ≤400x10^9/L After 12 Months

Time: 1 year

Measure: Platelet Count

Time: 1 year

Measure: Red Blood Cell (RBC) Count

Time: 1 year

Measure: White Blood Cell (WBC) Count

Time: 1 year

Measure: Differential WBC Count

Time: 1 year

Measure: Hemoglobin Concentration

Time: 1 year

Measure: Hematocrit Level

Time: 1 year
Time Perspective: Prospective

Case-Only

There is one SNP

SNPs

1 V617F

An Exploratory, Observational, Multicentre Study to Investigate the Impact of the Presence of JAK2 (V617F) Mutation on Treatment Response in Patients With Essential Thrombocythaemia Treated With XAGRID® (Anagrelide Hydrochloride). --- V617F ---

Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID® This study is hypothesis-generating to explore the impact of JAK2 (V617F) mutation status on the treatment response to anagrelide hydrochloride Number of Patients With Platelet Count ≤600x10^9/L After 12 Months. --- V617F ---


HPO Nodes

HPO:
Thrombocytosis
Genes 25
MPL IFNGR1 CD55 JAK2 TET2 ELANE RPS19 RPSA HMGCL TMEM173 ABL1 THPO RUNX1 ZMPSTE24 LMNA SH2B3 HBB BCR ACAT1 ADA2 MTHFD1 CALR TTC37 TBC1D24 PMM2